Bioterrorism and critical care

Critical Care Clinics

Volumn 19, Issue 2, 2003, Pages 279-313

  Karwa, Manoj ^a   Bronzert, Patricia ^a   Kvetan, Vladimir ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STAPHYLOCOCCUS ENTEROTOXIN A;

ALPHA VIRUS; ANTHRAX; BACTERIAL SPORE; BIOLOGICAL WARFARE; BOTULISM; BRUCELLA; BURKHOLDERIA; COXIELLA BURNETII; CRYPTOSPORIDIUM PARVUM; DIFFERENTIAL DIAGNOSIS; DISINFECTION; EPIDEMIC; ESCHERICHIA COLI; INTENSIVE CARE; PLAGUE; PRIORITY JOURNAL; REVIEW; RICKETTSIA PROWAZEKII; SALMONELLA; SMALLPOX; TULAREMIA; UNITED STATES; VIBRIO CHOLERAE; VIRUS HEMORRHAGIC FEVER;

ANTHRAX; BIOTERRORISM; CRITICAL CARE; DISASTER PLANNING; HUMANS; INTERNET; PLAGUE; TULAREMIA;

EID: 0037377753     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(02)00053-2     Document Type: Review

References (122)

1. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism related inhalational anthrax: the first 10 cases reported in the United States. Emerging Infectious Diseases 2001;7(6):933-44.
2. Tucker JB. Historical trends related to bioterrorism: an empirical analysis. Emerging Infectious Diseases 1999;5(4):498-504.
3. Kadivar H, Adams SC. Treatment of chemical and biological warfare injuries: insights derived from the 1984 Iraqi attack on Manjoon island. Mil Med 1984;156:171-7.
4. Stockholm International Peace Research Initiative. SIPRI fact sheet. Iraq: the UNSCOM experience. Available at: http://www.sipri.se/pubs/Factsheet/unscom.html. Accessed January 2, 2002.
5. Zalinskas RA. Iraq's biological weapons. The past as the future. JAMA 1997;278:418-24.
6. Henderson DA. The looming threat of bioterrorism. Science 1999;283:1279-82.
7. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlosk anthrax outbreak of 1979. Science 1994;266:1202-8.
8. Davis CJ. Nuclear blindness: an overview of the biological weapons programs of the former Soviet Union and Iraq. Emerging Infectious Diseases 1999;5(4):509-13.
9. Stephenson J. Confronting a biological Armageddon: experts tackle prospect of bioterrorism. JAMA 1997;276:349-51.
10. Torok TJ, Tauxe RV, Wise RP, et al. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 1997;278:389-95.
11. Report of a WHO group of consultants. Health aspects of chemical and biological weapons. Geneva (Switzerland): World Health Organization; 1970;98-9. Available at http://www.who. int/emc/deliberate_epi.html. Accessed January 2, 2002.
12. Inglesby TV, Grossman R, O'Toole T. A plague on your city: observations from TOPOFF. Clin Infect Dis 2001;32:436-45.
13. O'Toole T. Smallpox: an attack scenario. Emerging Infectious Disease 1999;5(4):540-6.
14. Rotz LD, Khan AS, Lillibridge SR, et al. Public health assessment of potential biological terrorism agents. Emerging Infectious Diseases 2002;8(2):225-30.
15. Khan AS, Sage MJ. The Centers for Disease Controls Strategic Planning Workgroup. Biological and chemical terrorism. Strategic plan for preparedness and response. MMWR 2000;49(RR-4):1-14.
16. NATO Handbook on the medical aspects of NBC defensive operations AmedP-6; Part II biological FM 8-9. Washington (DC): Departments of the Army, the Navy, and the Air Force; 1996. Availaable at: http://www.fas.org/nuke/guide/usa/doctrine/dod/fn8-9/toc.htm. Accessed November 7, 2001.
17. English JF, Cundiff MY, Malone JD, et al. APIC Bioterrorism Task Force & CDC Hospital Infections Program Bioterrorism Working Group bioterrorism readiness plan: a template for healthcare facilities April 1999. Available at: http://www.apic.org/educ/readinow.cfm. Accessed January 3, 2002.
18. Birerzvige A. Inhalation hazard from reaerosolized biological agents: a review, United States army chemical research, development and engineering center report No. TR-413, Aberdeen (MD): 1992.
19. Chinn KSK. Aerosol penetration of chemical protective overgarment [report No.DPG/ JCP-94/005]. Dugway (UT): Joint Contact Point Directorate, US Army Dugway Proving Ground; 1994.
20. Morrow PE, Yu CP. Models of aerosol behavior in airways. In: Moren F, Newhouse MT, Dolovich MB, editors. Aerosols in medicine: principles, diagnosis and therapy. New York: Elsevier Science Publishers (Biomedical Division); 1985. p. 149-91.
21. Sobel J, Khan AS, Swerdlow DL. Threat of a biological terrorist attack on the US food supply: the CDC perspective. Lancet 2002;359(9309):874-80.
22. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon; medical and public health management. JAMA 1999;281:1735-45.
23. Association of Professionals in Infection Control and Epidemiology/ Centers for the Study of Bioterrorism and Emerging Infections. Mass casualty disaster plan checklist: a template for health care facilities. Available at: http://www.apic.org/bioterror/checklist.doc. Accessed February 5, 2002.
24. Bames JM. Penicillin and B anthracis. J Pathol Bacteriol 1947;194:113-25.
25. Friedlander A, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239-42.
26. Brossier F, Mock M. Toxins of Bacillus anthracis. Toxicon 2001;39:1747-55.
27. Brachman PS. Inhalation anthrax. Ann N Y Acad Sci 1980;353:83-93.
28. Dahlgren CM, Buchanan LM, Decker HM, et al. Bacillus anthracis aerosols in goat hair processing mills. Am J Hyg 1960;72:24-31.
29. Walker JS, Lincoln RE, Klein F. Pathophysiological and biochemical changes in anthrax. Fed Proc 1967;26:1539-44.
30. Amramova FA, Grinberg LM, Yampolskaya O, et al. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak in 1979. Proc Natl Acad Sci U S A 1993;90:2291-4.
31. Kim HJ, Jun WB, Lee SH, et al. CT and MRI findings of anthrax meningoencephalitis: report of two cases and review of the literature. Am Soc Neurorad 2001;22:1303-5.
32. Franz DR, Jahrling PB, Friedlander A, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399-411.
33. Mayer TA, Matcha SB, Murphy C. Clinical presentation of inhalational anthrax following bioterrorism exposure; report of 2 surviving patients. JAMA 2001;286:2549-53.
34. Freedman A, Olumbunmi A, Chang MW, et al. Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7 month old infant. JAMA 2002;287(7):869-74.
35. Khajehdehi P. Toxemic shock, hematuria, hypokalemia, and hypoproteinemia in a case of cutaneous anthrax. Mt Sinai J Med 2001;68:213-5.
36. Mallon E, McKee PH. Extraordinary case report: cutaneous anthrax. Am J Dermatopathol 1997;19:79-82.
37. Vessal K, Yeganehdoust J, Dutz W, et al. Radiologic changes in inhalation anthrax. Clin Radiol 1975;26:471-4.
38. Lincoln RE, Klein F, Walker JS, et al. Successful treatment of monkeys for septicemic anthrax. In: Antimicrobial agents and chemotherapy - 1964. Washington (DC): American Society for Microbiology; 1965. p. 759-63.
39. Penn C, Klotz SA. Anthrax. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases. Philadelphia: WB Saunders; 1889. p. 1575-8.
40. Knisely RF. Selective medium for Bacillus anthracis. J Bacteriol 1966;92:784-6.
41. Miller JM. Agents of bioterrorism; preparing for bioterrorism at the community health care level. Infect Dis Clin 2001;15(4):1127-56.
42. Swartz MN. Recognition and management of anthrax-an update. N Engl J Med 2001;345(22):1621-6.
43. Centers for Disease Control and Prevention. CDC guidelines for state health departments on how to handle anthrax and other biological agent threats (revised Oct. 14, 2001). Available at: http://www.bt.cdc.gov. Accessed October 26, 2001.
44. Update. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR 2001;50:909-19. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042al.htm. Accessed February 16, 2002.
45. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon; medical and public health management. JAMA 2000;283:2281-90.
46. Centers for Disease Control and Prevention. Human plague-United States, 1993-1994. MMWR 1994;43:242-6.
47. Butler T. Yersinia species (including plague). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 2070-8.
48. Centers for Disease Control and Prevention. Fatal human plague. MMWR 1997;278:380-2.
49. Freidlander AM, McGovern TW. Plague. In: Sidell FR, Takafuji ET, Franz DR, editors. Textbook of military medicine. Part I: medical aspects of chemical and biological warfare. Washington (DC): Office of the Surgeon General, Department of the Army, United States of America; 1997. p. 479-502.
50. Dennis DT, Gage K, Gratz N, et al. Plague manual: epidemiology, distribution, surveillance and control, World Health Organization: communicable disease surveillance and response, 1999. Available at: http://www.who.int/emc_documents/plague/whocdscsredc992c.html. Accessed January 11, 2002.
51. Reyn CF, Weber NS, Tempest B, et al. Epidemiologic and clinical features of an outbreak of bubonic plague in New Mexico. J Infect Dis 1977;136(4):489-94.
52. Dennis JA, Mettler FA, Mann JM. Radiographic manifestations of plague in New Mexico, 1975-1980. Radiology 1981;139:561-5.
53. Dennis JC, Vemalo JR, Lombardi LJ, et al. Plague pneumonia: disease caused by Yersinia pestis. Semin Resp Inf 1997;12(1):12-23.
54. Florman AL, Spencer RR, Sheward S. Multiple lung cavities in a 12 year old girl with bubonic plague, sepsis, and secondary pneumonia. Am J Med 1986;80:1191-3.
55. Hull H, Montes JM, Mann JM. Septicemic plague in New Mexico. J Infect Dis 1987;155(1):113-8.
56. Wemer SB, Weidmer CE, Nelson BC, et al. Primary plague pneumonia contracted from a domestic cat in South Lake Tahoe, California. JAMA 1984;251:929-31.
57. Centers for Disease Control and Prevention. Pneumonic plague-Arizona. MMWR 1992;41:737-9.
58. Meyer K. Pneumonic plague. Bacteriological Reviews 1961;25:249-61.
59. Centers for Disease Control and Prevention. Prevention of plague: recommendations of the advisory committee on immunization practices. MMWR 1996;45:RR-14, 1-13.
60. Cross JT, Penn RL. Francisella tularensis tularemia. In: Mandell GL, Bennet JE, Dolin R, et al. editors. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2000. p. 2393-402.
61. Saslaw S, Eigelsbach HT, Prior JA, et al. Tularemia vaccine study, II: respiratory challenge. Arch Intern Med 1961;107:134-46.
62. Geyer SJ, Burkey A, Chandler FW. Tularemia. In: Connor DH, editor. Pathology of infectious diseases. Stamford (CT): Appleton & Lange; 1997. p. 869-73.
63. Evans ME, Gregory DW, Schaffner W, et al. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore) 1985;64:251-69.
64. Freidlander AM, Evans ME. Tularemia. In: Sidell FR, Takafuji ET, Franz DR, editors. Textbook of military medicine. Part I: medical aspects of chemical and biological warfare. Washington (DC): Office of the Surgeon General, Department of the Army, United States of America; 1997. p. 503-12.
65. Cunha BA, Gill V. Tularemia pneumonia. Semin Respir Infect 1997;12:61-7.
66. Sunderrajan EV, Hutton J, Marienfeld D. Adult respiratory distress syndrome secondary to tularemia pneumonia. Arch Intern Med 1985;145:1435-7.
67. Tualremia. In: Kortepeter M, Christopher G, Cieslak T, et al. editors. USAMRIID's medical management of biological casualties handbook. 4th edition. Ft. Detrik (MD): 2001. p. 37-43. Available at: http://www.usamriid.army.mil/education/bluebook.html. Accessed February 18, 2002.
68. Overholt EL, Tigert WD, Kadull PJ, et al. An analysis of forty-two cases of laboratory acquired tularemia. Am J Med 1961;30:785-806.
69. Franz DR, Pitt LM, Clayton MA, et al. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In: DasGupta BR, editor. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press; 1993. p. 473-6.
70. Pettersson T, Nyberg P, Nordstrom D, et al. Similar pleural fluid in pleuropulmonary tularemia and tuberculous pleurisy. Chest 1996;109:572-5.
71. Dennis DT, Inglesby TV, Henderson DA. Tularemia as a biological weapon; medical and public health management. JAMA 2001;285:2763-73.
72. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998;129:221-8.
73. Centers for Disease Control and Prevention. Botulism in the United States 1899-1996: handbook for epidemiologists, clinicians, and laboratory workers. Atlanta: Centers for Disease Control and Prevention; 1998. Available at: http://www.cdc.gov/ncdod/dbmd/diseaseinfo/ botulism.pdf. Accessed March 5, 2002.
74. Gangarosa EJ, Donadio JA, Armstrong RW, et al. Botulism in the United States, 1899-1969. Am J Epidemiol 1971;93:93-101.
75. Mann JM, Martin S, Hoffman R, et al. Patient recovery from type A botulism: morbidity assessment following a large outbreak. Am J Public Health 1981;71:266-9.
76. Montecucco C. Clostridial neurotoxins: the molecular pathogenesis of tetanus and botulism. Curr Top Microbiol Immunol 1995;195:1-278.
77. Botulinum toxins. In: Middlebrook JL, Franz DR, editors. USAMRIID's medical management of biological casualties handbook. 4th edition. Washington (DC): USAMRIID; 2001. p. 63-70. Available at: http://www.usamriid.army.mil/education/bluebook.html. Accessed March 5, 2002.
78. Hughes JM, Blumenthal JR, Merson MH, et al. Clinical features of types A and B food-bome botulism. Ann Intern Med 1981;95:442-5.
79. Nowara WWS, Samet JM, Rosario PA. Early and late pulmonary complications of botulism. Arch Intem Med 1983;143:451-6.
80. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998;21:701-10.
81. Santos JI, Swensen P, Glasgow LA. Potentiation of Clostridium botulinum toxin by aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981;68:50-4.
82. Schulze J, Toepfer M, Schroff KC, et al. Clindamycin and nicotinic neuromuscular transmission. Lancet 1999;354:1792-3.
83. Amon SS, Schecter R, Inglesby TV. Botulinum toxin as a biological weapon; medical and public health management. JAMA 2001;285:1059-70.
84. World Health Organization. The global eradication of smallpox: final report of the Global Commission for the Certification of Smallpox Eradication. Geneva (Switzerland): World Health Organization; 1980.
85. Mcclain DJ. Smallpox. In: Sidell FR, Takafuji ET, Franz DR, editors. Textbook of military medicine. Part I: medical aspects of chemical and biological warfare. Washington (DC): Office of the Surgeon General, Department of the Army, United States of America; 1997. p. 539-61.
86. Fenner F, Henderson DA, Arita I, et al. Smallpox and its eradication. Geneva (Switzerland): World Health Organization; 1988. p. 1-68. Available at: http://www.who.int/emc/diseases/ smallpox/Smallpoxeradication.html. Accessed December 12, 2001.
87. Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med 2002;346(17):1300-8.
88. Koplan, JP, Foster SO. Smallpox: clinical types, causes of death, and treatment. J Infect Dis 1979;140(3):440-1.
89. Esposito JJ, Massung RF. Poxvirus infections in humans. In: Murray PR, Tenover F, Baron EJ, editors. Clinical microbiology. Washington (DC): American Society of Microbiology; 1995. p. 1131-8.
90. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: medical and public health management. JAMA 1999;281:2127-37.
91. Meltzer MI, Damon I, LeDuc JW, et al. Modeling potential responses to smallpox as a bioterrorist weapon. Emerging Infectious Diseases 2001;7(6):959-69.
92. Frey SE, Couch RB, Tacket CO, et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002;346:1265-74.
93. Centers for Disease Control and Prevention. Vaccinia (smallpox) vaccine recommendations of the advisory committee on immunization practices (ACIP), 2001. MMWR Morb Mortal Wkly Rpt 2001;50(RR 10):1-25.
94. Jahrling PB. Viral hemorrhagic fevers. In: Sidell FR, Takafuji ET, Franz DR, editors. Textbook of military medicine. Part I: medical aspects of chemical and biological warfare. Washington (DC): Office of the Surgeon General, Department of the Army, United States of America; 1997. p. 591-602.
95. Centers of Disease Control and Prevention. Notice to readers update: management of patients with suspected viral hemorrhagic fever-United States. MMWR Morb Mortal Wkly Rpt 1995;44(25):475-9.
96. McCormick JB, King IJ, Webb PA, et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 1987;155:445.
97. Peters CJ. Arenaviridae and Bunyaviridae. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone; 1995. p. 1856-62.
98. Bruno P, Hassell LH, Brown J, et al. The protean manifestations of hemorrhagic fever with renal syndrome: a retrospective review of 26 cases from Korea. Ann Intern Med 1990;113:385-91.
99. Ketai LH, Williamson MR, Telepak RJ, et al. Hantavirus pulmonary syndrome: radiographic findings in 16 patients. Radiology 1994;191:665.
100. Moolenaar RL, Dalton C, Lipman HB, et al. Clinical features that differentiate Hantavirus pulmonary syndrome from three other acute respiratory illnesses. Clin Infect Dis 1995;21:643-9.
101. Hallin G, Simpson S, Cromwell R, et al. Cardiopulmonary manifestations of Hantavirus pulmonary syndrome. Crit Care Med 1996;24:252-8.
102. Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 1999;179(Suppl 1): S1-7.
103. Heyman DL, Barakamfitye D, Szczeniowski M, et al. Ebola hemorrhagic fever: lessons learned from Kikwit, Democratic Republic of the Congo. J Infect Dis 1999;179(Suppl 1):S283-6.
104. Cohen SN, Halstead SB. Shock associated with dengue infection. I. The clinical and physiologic manifestations of dengue hemorrhagic fever in Thailand, 1964. J Pediatr 1966;68:448.
105. Kautner I, Robinson MJ, Kuhnle U. Dengue virus infection: epidemiology, pathogenesis, clinical presentation, diagnosis and prevention. J Pediatr 1997;131:516.
106. Soni A, Chugh K, Sachdev A, et al. Management of dengue in ICU. Indian J Pediatr 2001;68(11):1051-5.
107. Q fever. In: Middlebrook JL, Franz DR, editors. USAMRIID's medical management of biological casualties handbook. 4th edition. Ft. Detirk (MD): USAMRIID; 2001. p. 33-6. Available at: http://www.usamriid.army.mil/education/bluebook.html. Accessed March 5, 2002.
108. Ulrich RG, Sheldon S, Taylor T, et al. Staphylococcal enterotoxin B and related pyrogenic toxins. In: Sidell FR, Takafuji ET, Franz DR, editors. Textbook of military medicine. Part I: medical aspects of chemical and biological warfare. Washington (DC): Office of the Surgeon General, Department of the Army, United States of America; 1997. p. 621-30.
109. Smith JF, Davis KY, Hart MK, et al. Viral encephalitides. In: Sidell FR, Takafuji ET, Franz DR, editors. Textbook of military medicine. Part I: medical aspects of chemical and biological warfare. Washington (DC): Office of the Surgeon General, Department of the Army, United States of America; 1997. p. 561-91.
110. Wilhelmsen C, Pitt L. Lesions of acute inhaled lethal ricin intoxication in rhesus monkeys. Vet Pathol 1993;30:482-90.
111. Society of Critical Care Medicine's vision for critical care [editorial]. Crit Care Med 1994;22:1713.
112. Wetter DC, Daniell WE, Treser CD. Hospital preparedness for victims of chemical or biological terrorism. Am J Public Health 2001;91:710-6.
113. Angus DC, Kvetan V. Organization and management of critical care in unconventional situations. Critical Care Clinics 1991;7(2):521-42.
114. Fraser DW, Tsai TR, Orenstein W, et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977;297:1189.
115. Mulazimoglu L. Can Legionnaires disease be diagnosed by clinical criteria? A critical review. Chest 2001;120(4):1049-53.
116. Sopena N, Leal MS, Botet MLP, et al. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest 1998;113(5):1195-200.
117. Tan MJ, Tan JS, Hamor RH, et al. The radiologic manifestations of Legionnaire's disease. Chest 2000;117(2):398-403.
118. Oliveira EC, Marik PE, Colice G. Influenza pneumonia: a descriptive study. Chest 2001;119:1717-23.
119. De Bleecker J, Van den Abeele K, De Reuck J. Electromyography in relation to end-plate acetylcholinesterase in rats poisoned by different organophosphates. Neurotoxicology 1994;15(2):331-40.
120. Sidell FR. Nerve agents. In: Sidell FR, Takafuji ET, Franz DR, editors. Textbook of military medicine. Part I: medical aspects of chemical and biological warfare. Washington (DC): Office of the Surgeon General, Department of the Army, United States of America; 1997. p. 129-81.
121. Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack. Emerging Infectious Diseases 1997;3:83-94.
122. Keim M, Kaufman AF. Principles for emergency response to bioterrorism. Ann Emerg Med 1999;34(2):177-82.